COMMUNIQUÉS West-GlobeNewswire
-
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
26/10/2025 -
New Global Coalition Launches to Address the Hidden Threat of RSV in Adults
26/10/2025 -
MapLight Therapeutics Announces Pricing of Initial Public Offering
26/10/2025 -
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
26/10/2025 -
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
26/10/2025 -
mediCAD® 8 Revolutionizes Orthopedic and Trauma Planning with Intelligent AI Integration
26/10/2025 -
Polpharma Group annonce un changement de direction – Sebastian Szymanek nommé nouveau président
26/10/2025 -
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
25/10/2025 -
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
25/10/2025 -
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
25/10/2025 -
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
25/10/2025 -
Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025
25/10/2025 -
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
25/10/2025 -
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
25/10/2025 -
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
25/10/2025 -
Aletheia Capital Endeavours Launches RepIntel, a Campaign-Grade Platform to Accelerate Global Access to Therapies
25/10/2025 -
Prenetics Global Limited Announces Proposed Public Offering
25/10/2025 -
Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences
24/10/2025 -
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
24/10/2025
Pages